Market Cap | 20.40M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -11.92M | Forward P/E | -0.38 | EPS next Y | - | 50D Avg Chg | -16.00% |
Sales | 7.16M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -28.00% |
Dividend | N/A | Price/Book | 0.34 | EPS next 5Y | - | 52W High Chg | -64.00% |
Recommedations | 3.00 | Quick Ratio | 1.29 | Shares Outstanding | 29.72M | 52W Low Chg | 14.00% |
Insider Own | 3.61% | ROA | -13.80% | Shares Float | 23.42M | Beta | 0.20 |
Inst Own | 23.51% | ROE | -32.16% | Shares Shorted/Prior | 845.17K/1.47M | Price | 0.70 |
Gross Margin | -43.79% | Profit Margin | - | Avg. Volume | 85,154 | Target Price | 0.50 |
Oper. Margin | -288.74% | Earnings Date | May 9 | Volume | 37,480 | Change | -0.85% |
Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.
Goldman Sachs | Neutral | Aug 16, 22 |
BTIG | Buy | Jun 24, 22 |
BTIG | Buy | Apr 27, 22 |
Goldman Sachs | Neutral | Apr 14, 22 |
BTIG | Neutral | Jan 20, 22 |
Canaccord Genuity | Hold | Jan 14, 22 |
JP Morgan | Underweight | Nov 12, 21 |
Canaccord Genuity | Buy | Nov 12, 21 |
Goldman Sachs | Neutral | Oct 22, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Huennekens R Scott | Director Director | Jun 03 | Sell | 0.58 | 60,000 | 34,800 | 507,509 | 06/03/22 |